View Post

Rare Patient Voice: Paid Opportunity for Follicular Lymphoma & Mantle Cell Lymphoma Patients in the US

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: 60 min interview + 10 min pre-task Compensation $120 * Companies have finally realized the REAL EXPERTS are the Patients and Caregivers! * Better products, services, and treatments, Start with Better Research. They need YOUR input and are willing to pay $100 an hour for it! Signup Today and let YOUR Voice be heard! Why Sign up with …

View Post

Rare Patient Voice: Study Opportunity for Non-Hodgkin’s Lymphoma, Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia Patients

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: 60 min Web-Assisted Phone Interview Compensation $100 Now accepting Residents from ALL Countries!! * Companies have finally realized the REAL EXPERTS are the Patients and Caregivers! * Better products, services, and treatments, Start with Better Research. They need YOUR input and are willing to pay $100 an hour for it! Signup Today and let YOUR Voice be heard! …

View Post

Rare Patient Voice: Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Acute Lymphoblastic Leukemia Patients and Caregivers

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: 20 min Online Survey Compensation $25 Please sign up at the link below for more information or to see if you qualify. http://letlife.in/rare-patient-voice Why Sign up with Rare Patient Voice? Who knows better than you about your journey and experiences?  We connect you with researchers who are developing products and services which can help you and others with …

View Post

FDA Okays New CAR T Therapy, First for Mantle Cell Lymphoma

In Clinical Studies News by Barbara Jacoby

By: Nick Mulcahy From: medscape.com The US Food and Drug Administration (FDA) today granted accelerated approval to brexucabtagene autoleucel (Tecartus, Kite Pharma), the first approved chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). The new agent is the second approved CAR T cell product developed by Kite and follows …

View Post

Gilead to get speedy FDA review for second CAR-T cell therapy in lymphoma

In Clinical Studies News by Barbara Jacoby

By: Alaric DeArment From: medcitynews.com The biotech company’s Kite Pharma subsidiary said the FDA had granted priority review for KTE-X19 in mantle cell lymphoma. The company already markets the CAR-T Yescarta for diffuse large B-cell lymphoma. A subsidiary of Gilead Sciences could have its second CAR-T cell therapy on the market by this summer if the Food and Drug Administration …

View Post

FDA Clears New Option for Mantle Cell Lymphoma

In Clinical Studies News by Barbara Jacoby

By: Megan Brooks From: medscape.com The US Food and Drug Administration (FDA) has granted an accelerated approval to zanubrutinib (Brukinsa, BeiGene USA Inc) capsules for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy. “Mantle cell lymphoma usually responds well to initial treatment, but eventually returns or stops responding, and the cancer cells …

View Post

Doctors hail drug that can ‘turn off cancer’: Once-a-day tablet could spare …

In In The News by Barbara Jacoby

By Hilary Freeman From: dailymail.co.uk A revolutionary drug that ‘switches off’ cancer may soon be offered to patients with some forms of the disease. If prescribed, the once-a-day tablet, called ibrutinib, could spare blood cancer patients the sometimes agonising side effects of traditional chemotherapy. Ibrutinib is one of only a handful of new medicines to be made available via the …